Esperion, Again: Pfizer's First Spin-Out's Familiar Look
This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.
You may also be interested in...
As it divests assets to restructure its research and development pipeline, Pfizer Inc. has found the best buyers are intimately familiar with what they're getting. In late July, the big pharma revealed it sold its Idun Pharmaceuticals Inc. subsidiary to Conatus Pharmaceuticals Inc., a startup founded by the same executives who led Idun prior to its nearly $300 million acquisition by Pfizer in 2005.
Corporate venture groups are poised to become one of the main sources of funding for early-stage biotechs thanks to the current economic climate. Even if corporate venture groups invest at the same levels as previous years, some industry veterans believe they could play a role in up to half of the early-stage financings this year, largely because the traditional sources of financing--the public market and venture capital groups flush with cash--have disappeared. And the new vigor of corporate venture offers big benefits to both small biotechs and Big Pharma.
Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.